Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression;Potencjalizacja leków przeciwdepresyjnych kwasami tłuszczowymi omega-3 w depresji lekoopornej

Psychiatria Polska

Volumn 46, Issue 4, 2012, Pages 585-598

  Krawczyk, Kamila ^a   Rybakowski, Janusz ^a  

^a Poznan University of Medical Sciences   (Poland)

Author keywords

Depression; Fatty acids omega 3; Treatment

Indexed keywords

ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LAMOTRIGINE; LITHIUM; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PAROXETINE; PRIMROSE OIL; VENLAFAXINE;

ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG CAPSULE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HAMILTON SCALE; HUMAN; RECURRENT DISEASE; SYMPTOM; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; POLAND; RECURRENCE; TREATMENT OUTCOME; TRIAZINES;

EID: 84866463377     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Pawełczyk A, Pawełczyk T, Rabe-Jabłońska J. Egzogenne wielonienasycone kwasy tłuszczowe moga̧ poprawiać sprawność wybranych funkcji poznawczych. Psychiatr. Psychol. Klin. 2008; 8: 178-191.
2. Tanskanen A, Hibbeln JR, Tuomilehto J i in. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr. Serv. 2001; 52: 529-531. (Pubitemid 32275317)
3. Weissman MM, Bland RC, Canino GJ i in. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-299. (Pubitemid 26249533)
4. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer HY. Fatty acid composition in major depression: decreased omega-3 fractions in cholesteryl esters and increased C20:4 omega-6/C20:5 omega-3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 1996; 38: 35-46.
5. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999; 85: 275-291. (Pubitemid 29202389)
6. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandyn E2 and thromboxane B2 in depression. Prostagland. Leukot. Med. 1983; 10: 361-367. (Pubitemid 13162267)
7. Smith RS. The macrophage theory of depression. Med. Hypoth.1991; 35: 298-306.
8. Song C, Lin A, Bonaccouso S i in. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998; 49: 211-219. (Pubitemid 28218842)
9. Blalock JE. A molecular basis for bidirectional communications between the immune and neuroendocrine systems. Physiol. Rev. 1986; 69: 1-32. (Pubitemid 19040135)
10. Reichlin S. Neuroendocrine-immune interactions. N. Engl. J. Med. 1993; 329: 1246-1253.
11. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005; 15: 159-166. (Pubitemid 40546172)
12. Calder PC. N-3 polyunsturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006; 83: 1505-1519.
13. Capuron L, Neurater G, Musselman DL. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 20003; 54: 906-914.
14. Ryś A, Miodek A, Szemraj P i in. Immunologiczne i endokrynologiczne aspekty patogenezy depresji. Post. Psychiatr. Neurol. 2007; 16: 335-337. (Pubitemid 351166555)
15. Huan M, Hamazaki K, Sun Y, Itomura M, Liu H, Kang W, Watanabe S, Terasawa K, Hamazaki T. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol. Psychiatry 2004; 56 (7): 490-496. (Pubitemid 39278246)
16. McNamara RK, Ostrander M, Abplanalp W i in. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostagland. Leukot. Essent. Fatty Acids 2006; 75: 237-257. (Pubitemid 44442916)
17. Vaidyanathan VV, Rao KV, Sastry PS. Regulation of diacylglycerol kinase in rat brain membranes by docosahexaenoic acid. Neurosc. Lett. 1994; 179: 171-174. (Pubitemid 24298585)
18. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationship to impaired fatty acids and phospholipid metabolism and to diadetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possoble candidate genes. Prostagland. Leukot. Essent. Fatty Acids 1999; 60: 217-234. (Pubitemid 29306598)
19. Leviel V, Naquet R. A study of the action of valproic acid on the kindling effect. Epilepsia 1997; 18: 229-234.
20. Sanders-Bush E, Tsutsumi M, Burris K. Serotonin receptors and phosphatidylinositol turnover. Ann. NY Acad. Sc. 1990; 600: 224-235.
21. Stoll AL, Severus WE. Mood stabilizers: shared mechanisms of action at post synaptic signal transduction and kindling processes. Harvard Rev. Psychiatr. 1996; 4: 77-89. (Pubitemid 26279871)
22. Assies J, Lok A, Bockting CL i in. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostagland. Leukot. Essen. Fatty Acids 2004; 70: 349-56. (Pubitemid 38429267)
23. Karakuła H, Opolska A, Kowal A i in. Czy dieta ma wpływ na nasz nastrój? Znaczenie kwasu foliowego i homocysteiny. Pol. Merkur. Lek. 2009; 26: 136-141.
24. Graban A, Ryglewicz D. Zaburzenia metabolizmu homocysteiny a choroby układu nerwowego. Czynn. Ryz. 2004; 1/2: 33-37.
25. Bolander-Gouaille Ch, Bottiglieri T. Homocysteine, related vitamins and neuropsychiatric disorders. New York, LLC: Springen-Verlag; 2003.
26. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanism and therapeutic value in major depression. Altern. Med. Rev. 2003; 8: 410-425. (Pubitemid 37493870)
27. Nements B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenace medication treatment for reccurent unipolar depreesive disorder . Am. J. Psychiatry 2002; 159: 477-479. (Pubitemid 34184747)
28. Su KP, Huang SY, Chiu CC i in. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo controlled trial. Eur. Neuropsychopharmacol. 2003; 13: 267-271. (Pubitemid 36904053)
29. Peet M, Edwards RW, Horrobin DF. N-3 fatty acids in the treatment of depression. W: Peet M, Glen I, Horrobin DF, red. Phospholipid spectrum disorders in psychiatry and neurology. Marius Press; 2003, s. 463-467.
30. Jazayeri S, Tehrani-Doost M, Keshavarz SA i in. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Austr. NZJ Psychiatry 2008; 42: 192-198. (Pubitemid 351234188)
31. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 2007; 68: 1056-1061. (Pubitemid 47340326)
32. Freeman MP, Hibbeln JR, Wisner KL i in. An open trial of omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr. 2006; 18: 21-24.
33. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr. 2009; 28: 525-542.
34. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E i in. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999; 56: 407-412. (Pubitemid 29215428)
35. Peet M, Horrobin DF. A dose ranging study of the effects of ethyl eicosapentaeonate in patients with ongoing depression in spite of apperently adequate treatment with standard drugs. Arch. Gen. Psychiatry 2002; 59: 913-919.
36. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Brit. J. Psychiatry 2006; 188: 46-50. (Pubitemid 43021926)
37. Osher Y, Berssudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry 2005; 66: 726-729. (Pubitemid 40942418)
38. Marangell LB, Martinez JM, Zboyan HA i in. A double-blind, placebo-controlled study of omega-3 fatty acid docosahexaenoic acid in the treament of major depression . Am. J. Psychiatry 2003; 160: 996-998. (Pubitemid 41079588)
39. Silvers KM, Woolley CC, Hamilton FC i in. Randomized double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostagland. Leukot. Essent. Fatty Acids 2005; 72: 211-218. (Pubitemid 40139086)
40. Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentation. Eur. Neuropharmacol. 1992; 2: 161-165.
41. Pużyński S. Depresja lekooporna. Terapia 2005; 11: 27-33.
42. Walter G, Lyndon, Kubb R. Lithium augmentation of venlafaxine in adolescent major depression. Aust. NZJ Psychiatry 1998; 32: 457-459. (Pubitemid 28306370)
43. Bertschy G, Ragama-Pardos E, Ait-Ameur A i in. Lithium augmentation in venlafaxinenonresponders: an open study. Eur. Psychiatry 2003; 18: 314-317. (Pubitemid 37461924)
44. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J. Clin. Psychiatry 2007; 68: 935-940. (Pubitemid 47015495)
45. Pużyński S. Postȩpowanie w depresji lekoopornej. Farmakoter. Psychiatr. Neurol. 2007; 1: 23-29.
46. Rybakowski J, Tuszewska M, Chłopocka-Woźniak M. Potencjalizacja leków przeciwdepresyjnych w depresji opornej na leczenie za pomoca̧ litu lub lamotriginy (badania wstepne). Farmakoter. Psychiatr. Neurol. 2009; 1: 17-21.
47. Normann C, Hummel B, Scharer LO i in. Lamotrigine as adjunct to paroxetne in acute depression: a placebo-conntrolled, double-blind stydy. J. Clin. Psychiatry 2002; 63: 337-344. (Pubitemid 34456362)
48. Schindler F, Anghelescu ID. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized open-label study. Int. Clin. Psychopharmacol. 2007: 22: 179-182. (Pubitemid 46559875)
49. Suppes T, Marangell L, Bernstein IH i in. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J. Affect. Disord. 2008; 111: 334-343.
50. Ivković M, Damjanović A, Jovanović A i in. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. Psychiatr. Danub. 2009; 21: 187-193.
51. Appleton KM, Hayward RC, Gunnel D i in. Effect of n-3 long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am. J. Clin. Nutr. 2006; 84: 1308-1316. (Pubitemid 44912811)
52. Rogers PJ, Appleton KM, Kessler D i in. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Brit. J. Nutr. 2008; 99: 421-431.
53. Maki KC, Bays HE, Dicklin MR i in. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A(2) mass in men and women with mixed dyslipidemia. J. Clin. Lipidol. 2011; 5 (6): 483-492.
54. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011; 58 (20): 2047-2067.
55. Hofacer R, Jack Magrisso I, Jandacek R i in. Omega-3 fatty acid deficiency increases stearoyl-CoA desaturase expression and activity indices in rat liver: Positive association with non-fasting plasma triglyceride levels. Prostagland. Leukot. Essent. Fatty Acids. 2011; 31.
56. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis. Curr. Atheroscler. Rep. 2011;
57. Sadeghi M, Roohafza H, Afshar H i in. Relationship between depression and apolipoproteins A and B: a case-control study. Clinics (Sao Paulo) 2011; 66: 113-117.
58. Laino CH, Fonseca C, Sterin-Speziale N i in. A potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine. Eur. J. Pharmacol. 2010; 648: 117-126.